home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

45 rows where docket_id = "FDA-2026-P-6737" sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, open_for_comment, posted_date (date), comment_start_date (date), last_modified (date)

document_type 2

  • Supporting & Related Material 43
  • Other 2

posted_year 1

  • 2026 45

agency_id 1

  • FDA 45
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2026-P-6737-0009 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:46Z   0 0 09000064b932a303
FDA-2026-P-6737-0012 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:55Z   0 0 09000064b932a306
FDA-2026-P-6737-0003 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:26Z   0 0 09000064b932a273
FDA-2026-P-6737-0008 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:43Z   0 0 09000064b932a302
FDA-2026-P-6737-0043 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:44Z   0 0 09000064b932a33d
FDA-2026-P-6737-0040 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:34Z   0 0 09000064b932a33a
FDA-2026-P-6737-0045 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:50Z   0 0 09000064b932a33f
FDA-2026-P-6737-0030 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 28 - Skin-Related Adverse Reactions in Gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:56Z   0 0 09000064b932a326
FDA-2026-P-6737-0015 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 13 - Prepubertal exposure to gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:05Z   0 0 09000064b932a309
FDA-2026-P-6737-0018 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:15Z   0 0 09000064b932a30e
FDA-2026-P-6737-0037 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:23Z   0 0 09000064b932a337
FDA-2026-P-6737-0005 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 3 - Gadolinium retention effect on macrophages Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:32Z   0 0 09000064b932a275
FDA-2026-P-6737-0021 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 19 - Gadolinium-based contrast agent toxicity Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:25Z   0 0 09000064b932a311
FDA-2026-P-6737-0024 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 22 - Gadolinium deposition in bone tissues after contrast-enhanced Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:37Z   0 0 09000064b932a314
FDA-2026-P-6737-0044 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:47Z   0 0 09000064b932a33e
FDA-2026-P-6737-0041 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 39 - Delineating toxicity mechanisms associated with MRI contrast Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:37Z   0 0 09000064b932a33b
FDA-2026-P-6737-0023 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 21 - Influence blocking by Gadolinium in Calcium Diffusion Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:33Z   0 0 09000064b932a313
FDA-2026-P-6737-0006 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:36Z   0 0 09000064b932a300
FDA-2026-P-6737-0007 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:40Z   0 0 09000064b932a301
FDA-2026-P-6737-0010 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 8 - Repeated gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:50Z   0 0 09000064b932a304
FDA-2026-P-6737-0019 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:19Z   0 0 09000064b932a30f
FDA-2026-P-6737-0011 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 9 - Gadolinium Mitochondrial Toxicity Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:52Z   0 0 09000064b932a305
FDA-2026-P-6737-0017 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:11Z   0 0 09000064b932a30d
FDA-2026-P-6737-0028 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 26 - Neurotoxicity from intrathecal gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:49Z   0 0 09000064b932a324
FDA-2026-P-6737-0031 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 29 - Acute lung injury following gadolinium contrast Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:00Z   0 0 09000064b932a327
FDA-2026-P-6737-0033 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:07Z   0 0 09000064b932a329
FDA-2026-P-6737-0004 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:30Z   0 0 09000064b932a274
FDA-2026-P-6737-0026 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 24 - Effects of Gadolinium-Based MRI Contrast Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:43Z   0 0 09000064b932a322
FDA-2026-P-6737-0014 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:02Z   0 0 09000064b932a308
FDA-2026-P-6737-0022 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 20 - Human Hair as a Possible Surrogate Marker of Retained Tissue Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:30Z   0 0 09000064b932a312
FDA-2026-P-6737-0013 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 11 - On the interaction of muscle actin with gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:58Z   0 0 09000064b932a307
FDA-2026-P-6737-0016 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:09Z   0 0 09000064b932a30c
FDA-2026-P-6737-0036 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:20Z   0 0 09000064b932a336
FDA-2026-P-6737-0042 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:40Z   0 0 09000064b932a33c
FDA-2026-P-6737-0001 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Citizen Petition from Regina Sutton Other Citizen Petition 2026-06-15T04:00:00Z 2026 6 2026-06-15T04:00:00Z   2026-06-15T20:27:13Z   1 0 09000064b9329d15
FDA-2026-P-6737-0002 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Acknowledgement Letter from FDA DMB to Regina Sutton Other Acknowledgement Letter/Receipt 2026-06-15T04:00:00Z 2026 6 2026-06-15T04:00:00Z   2026-06-15T20:27:18Z   0 0 09000064b9329d18
FDA-2026-P-6737-0025 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 23 - Assessment of gadolinium and iodine concentrations in kidney stones Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:40Z   0 0 09000064b932a315
FDA-2026-P-6737-0032 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:03Z   0 0 09000064b932a328
FDA-2026-P-6737-0027 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:46Z   0 0 09000064b932a323
FDA-2026-P-6737-0020 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 18 - Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:22Z   0 0 09000064b932a310
FDA-2026-P-6737-0034 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 32 - Caught in the act Allergic-like reaction to Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:10Z   0 0 09000064b932a32a
FDA-2026-P-6737-0038 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 36 - Effects of gadolinium Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:26Z   0 0 09000064b932a338
FDA-2026-P-6737-0029 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:28:52Z   0 0 09000064b932a325
FDA-2026-P-6737-0035 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent. Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:16Z   0 0 09000064b932a32b
FDA-2026-P-6737-0039 FDA Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 Reference 37 - Gadolinium Contrast Agent Deposition in Children Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:29:30Z   0 0 09000064b932a339

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 5.559ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API